These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29476348)

  • 1. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
    Hu J; Deng A; Zhao Y
    Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Frias JP
    Expert Rev Endocrinol Metab; 2019 Mar; 14(2):75-83. PubMed ID: 30724637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
    Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
    [No Abstract]   [Full Text] [Related]  

  • 8. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
    Yang J
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):747-753. PubMed ID: 30025475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Ji L; Liu Y; Miao H; Xie Y; Yang M; Wang W; Mu Y; Yan P; Pan S; Lauring B; Liu S; Huyck S; Qiu Y; Terra SG
    Diabetes Obes Metab; 2019 Jun; 21(6):1474-1482. PubMed ID: 30830724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
    [No Abstract]   [Full Text] [Related]  

  • 12. Ertugliflozin + metformin as a treatment option for type 2 diabetes.
    Athyros VG; Boutari C; Karagiannis A
    Expert Opin Pharmacother; 2021 Nov; 22(16):2105-2111. PubMed ID: 34130582
    [No Abstract]   [Full Text] [Related]  

  • 13. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ertugliflozin alone and in fixed-dose combinations : «pass of three»].
    Scheen AJ
    Rev Med Liege; 2020 Sep; 75(9):626-632. PubMed ID: 32909416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
    Sahasrabudhe V; Fediuk DJ; Matschke K; Shi H; Liang Y; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Dawra VK
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):619-627. PubMed ID: 30427588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart K; Carris NW
    Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
    Powell J; Garland SG
    Ann Pharmacother; 2019 May; 53(5):478-485. PubMed ID: 30522346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.
    Cinti F; Moffa S; Impronta F; Cefalo CM; Sun VA; Sorice GP; Mezza T; Giaccari A
    Drug Des Devel Ther; 2017; 11():2905-2919. PubMed ID: 29042751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.